Table 3.
Results of meta-analysis for PON1-Q192R polymorphism and cancer risk.
| Variables | Case/control | R vs. Q | RR vs. QQ | RQ vs. QQ | RR+RQ vs. QQ | RR vs. RQ+QQ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR(95% CI) | pa | I2(%) | OR(95% CI) | pa | I2(%) | OR(95% CI) | pa | I2(%) | OR(95% CI) | pa | I2(%) | OR(95% CI) | pa | I2(%) | ||
| Total | 11412/13936 | 0.897(0.798-1.008) | 0 | 86.8 | 0.855(0.683-1.073) | 0 | 81.1 | 0.861(0.724-1.023) | 0 | 86.7 | 0.857(0.730-1.008) | 0 | 86.7 | 0.914(0.758-1.102) | 0 | 78.1 |
| Breast cancer | 2005/2748 | 0.643(0.440-0.942) ∗ | 0 | 91.4 | 0.542(0.331-0.886)∗ | 0 | 74 | 0.529(0.325-0.861)∗ | 0 | 89.1 | 0.534(0.330-0.865)∗ | 0 | 90.6 | 0.720(0.492-1.054) | 0.010 | 62.3 |
| Gastrointestinal cancer | 1752/2356 | 1.008(0.700-1.450) | 0 | 88.1 | 0.969(0.463-2.025) | 0.000 | 80.2 | 1.079(0.761-1.529) | 0.002 | 75.7 | 1.038(0.682-1.580) | 0.000 | 85.0 | 0.968(0.547-1.711) | 0.013 | 68.5 |
| Prostate cancer | 2261/2891 | 0.967(0.886-1.055) | 0.748 | 0 | 0.563(0.313-1.015) | 0.001 | 83 | 1.544(0.969-2.458) | 0 | 90.9 | 1.249(1.030-1.514)∗ | 0.083 | 55 | 0.498(0.235-1.053) | 0 | 90.3 |
| Hematologic tumor | 2303/2355 | 1.113(0.852-1.453) | 0 | 85.5 | 1.358(0.787-2.341) | 0 | 82 | 0.943(0.740-1.202) | 0.007 | 62.3 | 1.040(0.774-1.397) | 0 | 78.2 | 1.364(0.863-2.157) | 0 | 77.8 |
| Lung cancer | 1172/1011 | 1.179(0.949-1.464) | 0.04 | 63.8 | 1.244(0.665-2.326) | 0.005 | 76.6 | 1.214(0.704-2.094) | 0.004 | 77.5 | 1.262(0.741-2.149) | 0.003 | 78.6 | 1.201(0.997-1.449) | 0.442 | 0 |
| Brain tumor | 1173/1395 | 0.759(0.505-1.140) | 0 | 89.2 | 0.576(0.266-1.248) | 0 | 85.9 | 0.778(0.539-1.124) | 0.006 | 69 | 0.696(0.431-1.123) | 0 | 84.4 | 0.698(0.388-1.256) | 0 | 79.4 |
| Ovarian cancer | 322/496 | 0.665(0.189-2.337) | 0 | 92.7 | 0.940(0.314-2.813) | 0.087 | 65.8 | 0.328(0.030-3.572) | 0 | 94.6 | 0.443(0.060-3.283) | 0 | 94.5 | 1.359(0.985-1.875) | 0.658 | 0 |
| Other cancers | 424/684 | 0.809(0.481-1.362) | 0 | 85.1 | 1.264(0.515-3.101) | 0.022 | 65 | 0.670(0.250-1.798) | 0 | 89.4 | 0.741(0.299-1.838) | 0 | 89.1 | 1.352(0.797-2.294) | 0.209 | 31.8 |
| Ethnicities | ||||||||||||||||
| Caucasian | 4424/6292 | 0.815(0.658-1.011) | 0 | 90.1 | 0.784(0.516-1.193) | 0 | 84.5 | 0.731(0.528-1.010) | 0 | 91.1 | 0.744(0.557-0.993)∗ | 0 | 90.3 | 0.893(0.608-1.311) | 0 | 83.5 |
| Asian | 3253/3629 | 0.840(0.840-1.244) | 0 | 89.9 | 1.019(0.689-1.506) | 0 | 78.5 | 1.020(0.779-1.337) | 0 | 76.3 | 1.022(0.758-1.377) | 0 | 83.0 | 1.052(0.850-1.303) | 0.025 | 54.4 |
| Mixed | 3735/4015 | 0.981(0.877-1.098) | 0.035 | 51.6 | 0.913(0.727-1.145) | 0.062 | 46.2 | 1.012(0.873-1.174) | 0.109 | 38.8 | 0.990(0.851-1.153) | 0.057 | 47 | 0.929(0.770-1.119) | 0.115 | 38.1 |
| Control source | ||||||||||||||||
| Population based | 6871/8354 | 0.849(0.717-1.004) | 0 | 88.8 | 0.802(0.604-1.065) | 0 | 79.1 | 0.793(0.638-0.984)∗ | 0 | 85 | 0.789(0.630-0.988)∗ | 0 | 87.9 | 0.920(0.749-1.130) | 0 | 70.3 |
| Hospital based | 4309/5667 | 0.897(0.798-1.008) | 0 | 85.1 | 0.948(0.655-1.374) | 0 | 83.2 | 0.927(0.704-1.221) | 0 | 87.3 | 0.923(0.726-1.175) | 0 | 85.5 | 0.967(0.696-1.342) | 0 | 83.3 |
| Genotype method | ||||||||||||||||
| PCR-RFLP | 5445/6900 | 0.884(0.735-1.064) | 0 | 88.4 | 0.888(0.735-1.064) | 0 | 88.4 | 0.815(0.607-1.094) | 0 | 90.4 | 0.839(0.646-1.091) | 0 | 89.4 | 0.938(0.692-1.271) | 0 | 80.5 |
| TaqMan | 5967/7036 | 0.922(0.801-1.060) | 0 | 83 | 0.834(0.622-1.117) | 0 | 81.3 | 0.952(0.824-1.099) | 0.001 | 61.1 | 0.906(0.762-1.078) | 0 | 76.7 | 0.915(0.736-1.139) | 0 | 73.5 |
Notes: ∗ statistically significant (P<0.05); P valuea: P value of Q test for heterogeneity test; I2: 0%–25% means no heterogeneity, 25%–50% means modest heterogeneity, and 50% means high heterogeneity. Abbreviations: CI, confidence interval; OR, odds ratio; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.